Orlistat
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Orlistat: From Obesity Management to Hypervitaminosis
One-Sentence Summary
Orlistat is a lipase inhibitor whose established clinical role is in weight management (obesity); however, the structured "original indication" field in this evidence pack is empty (data gap). The TxGNN model predicts a possible link to Hypervitaminosis, but this is currently supported by 0 clinical trials and 0 publications — prediction score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not populated in evidence pack (flagged as data gap, DG002); commonly known clinically as obesity/weight management (gastric & pancreatic lipase inhibitor) |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack's structured original_moa field (data gap DG002). However, the repurposing rationale supplied alongside the prediction describes the relevant pharmacology: Orlistat inhibits gastric and pancreatic lipase, blocking triglyceride hydrolysis and reducing intestinal fat absorption by roughly 30%.
This same lipase-inhibition mechanism also reduces intestinal absorption of the fat-soluble vitamins (A, D, E, K). That provides a theoretical, indirect rationale for using orlistat to lower circulating levels in cases of fat-soluble vitamin excess — such as hypervitaminosis A.
This link should be treated as inferential rather than mechanistically targeted: orlistat was not designed against hypervitaminosis pathology, and because both the original-indication field and the formal MOA field are data gaps, the pathway cannot be fully verified against source documentation at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Finland Market Information
Orlistat is not currently marketed in Finland — no marketing authorizations are on record (total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is model-generated only (L5), with no clinical trials or literature identified for hypervitaminosis. Critically, TFDA warning/contraindication data is missing and flagged as a Blocking gap (DG001) — the candidate cannot proceed to S1 safety initial review without it.
To proceed, the following is needed:
- TFDA package insert data — warnings and contraindications (DG001, Blocking; source: TFDA official site)
- Confirmed original indication and mechanism-of-action data via DrugBank (DG002, High)
- Preclinical or observational evidence directly linking lipase inhibition to fat-soluble vitamin clearance in hypervitaminosis
- Ongoing monitoring for new clinical trials or publications on this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.